Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

272.07
-0.3100-0.11%
Post-market: 272.070.00000.00%19:30 EDT
Volume:61.75K
Turnover:16.80M
Market Cap:2.95B
PE:31.84
High:273.14
Open:271.38
Low:270.78
Close:272.38
52wk High:273.14
52wk Low:171.06
Shares:10.85M
Float Shares:10.85M
Volume Ratio:0.74
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.55
EPS(LYR):37.75
ROE:19.96%
ROA:-0.16%
PB:2.22
PE(LYR):7.21

Loading ...

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
Jul 15

Bruker Acquires Noscendo’s Disqver Metagenomic Sequencing Platform

Reuters
·
Jul 15

Bruker Corp - Disqver Acquisition not Expected to be Material to Bruker FY26 Results

THOMSON REUTERS
·
Jul 15

Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic Mngs Disqver® Platform for Pathogenic Microorganisms in Blood

THOMSON REUTERS
·
Jul 15

Bruker Corp: Financial Details of Transaction were not Disclosed

THOMSON REUTERS
·
Jul 15

Bruker Corp : TD Cowen Raises Target Price to $60 from $45

THOMSON REUTERS
·
Jul 15

Veracyte Inc : Piper Sandler Initiates Coverage with Overweight Rating; Price Target $66

THOMSON REUTERS
·
Jul 15

Alkermes Schedules Second-quarter Results Call and Webcast

Reuters
·
Jul 15

Alkermes to Report Second Quarter Financial Results on July 28, 2026

THOMSON REUTERS
·
Jul 15

Veracyte is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Jul 14

Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?

Simply Wall St.
·
Jul 14

Voyager Therapeutics advances tau-silencing gene therapy program

TIPRANKS
·
Jul 14

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jul 14

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS
·
Jul 13

Alkermes Price Target Announced at $60.00/share by JP Morgan

Dow Jones
·
Jul 13

Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis

Reuters
·
Jul 13

Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested

THOMSON REUTERS
·
Jul 13

Alkermes - Alixorexton Shows Sustained Improvement on Mwt and ESS at Week 24, Nine Months After First Dose

THOMSON REUTERS
·
Jul 13

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults with Narcolepsy Type 1 and Type 2 in Long-term Extension Study Interim Analysis

THOMSON REUTERS
·
Jul 13

Bank of America Securities Remains a Sell on Alkermes (ALKS)

TIPRANKS
·
Jul 13